




Methodology for AACT evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning

Sophie Gosselin, Martin Morris, Andrea Miller-Nesbitt, Robert S. Hoffman, Bryan D. Hayes, Alexis F. Turgeon, Brian M. Gilfix, Ami M. Grunbaum, Theodore C. Bania, Simon H. L. Thomas, José A. Morais, Andis Gaudins, Benoit Bailey, Bruno Mégarbane, Diane P. Calello, Michael Levine, Samuel J. Stellpflug, Lotte C. G. Hoegberg, Ryan Chuang, Christine Stork, Ashish Bhalla, Carol J. Rollins, Valéry Lavergne & on behalf of the AACT Lipid Emulsion Therapy workgroup


To cite this article: Sophie Gosselin, Martin Morris, Andrea Miller-Nesbitt, Robert S. Hoffman, Bryan D. Hayes, Alexis F. Turgeon, Brian M. Gilfix, Ami M. Grunbaum, Theodore C. Bania, Simon H. L. Thomas, José A. Morais, Andis Gaudins, Benoit Bailey, Bruno Mégarbane, Diane P. Calello, Michael Levine, Samuel J. Stellpflug, Lotte C. G. Hoegberg, Ryan Chuang, Christine Stork, Ashish Bhalla, Carol J. Rollins, Valéry Lavergne & on behalf of the AACT Lipid Emulsion Therapy workgroup (2015) Methodology for AACT evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning, *Clinical Toxicology*, 53:6, 557-564, DOI: [10.3109/15563650.2015.1052498](https://doi.org/10.3109/15563650.2015.1052498)

To link to this article: <http://dx.doi.org/10.3109/15563650.2015.1052498>

 View supplementary material 

 Published online: 10 Jun 2015.

 Submit your article to this journal 

 Article views: 574

 View related articles 

 View Crossmark data 



Citing articles: 4 [View citing articles](#)

METHODOLOGY

Methodology for AACT evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning

SOPHIE GOSSELIN,¹ MARTIN MORRIS,² ANDREA MILLER-NESBITT,² ROBERT S. HOFFMAN,³ BRYAN D. HAYES,⁴ ALEXIS F. TURGEON,⁵ BRIAN M. GILFIX,⁶ AMI M. GRUNBAUM,⁶ THEODORE C. BANIA,⁷ SIMON H. L. THOMAS,⁸ JOSÉ A. MORAIS,⁹ ANDIS GRAUDINS,¹⁰ BENOIT BAILEY,¹¹ BRUNO MÉGARBANE,¹² DIANE P. CALELLO,¹³ MICHAEL LEVINE,¹⁴ SAMUEL J. STELLPFLUG,¹⁵ LOTTE C. G. HOEGBERG,¹⁶ RYAN CHUANG,¹⁷ CHRISTINE STORK,¹⁸ ASHISH BHALLA,¹⁹ CAROL J. ROLLINS,²⁰ VALÉRY LAVERGNE,²¹ and ON BEHALF OF THE AACT LIPID EMULSION THERAPY WORKGROUP*

¹Department of Emergency Medicine, Medical Toxicology Division, McGill University Health Centre, and Centre Antipoison du Québec, Québec, Québec, Canada

²Schulich Library of Science and Engineering, McGill University, Montréal, Québec, Canada

³Division of Medical Toxicology, Ronald O. Perelman Department of Emergency Medicine, New York University School of Medicine, New York, New York, USA

⁴Department of Pharmacy, University of Maryland Medical Center and Department of Emergency Medicine, University School of Medicine, Baltimore, Maryland, USA

⁵Division of Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, and CHU de Québec Research Center, Population Health and Optimal Health Practices Unit, Université Laval, Québec City, Québec, Canada

⁶Division of Medical Biochemistry, Department of Medicine, McGill University Health Centre, Montreal, Québec, Canada

⁷Department of Emergency Medicine, Mt Sinai Roosevelt, Mt Sinai St. Luke's, Icahn School of Medicine at Mt Sinai, New York, New York, USA

⁸National Poisons Information Service (Newcastle) and Medical Toxicology Centre, Institute of Cellular Medicine, Newcastle University, Newcastle, UK

⁹Department of Medicine, Crabtree Nutrition Laboratories, McGill University Health Centre, McGill University, Montreal, Québec, Canada

¹⁰Monash Emergency Medicine and Clinical Toxicology, Monash Health and Southern Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia

¹¹Division of Emergency Medicine, Department of Pediatrics, CHU Sainte-Justine, Montréal, Québec Canada, Centre Antipoison du Québec, Québec, Canada

¹²Department of medical and toxicological intensive care, Lariboisière Hospital, Paris-Diderot University, Paris, France

¹³Medical Toxicology, Department of Emergency Medicine, Morristown Medical Center, Emergency Medical Associates, Morristown, New Jersey, USA

¹⁴Department of Emergency Medicine, Section of Medical Toxicology, University of Southern California, Los Angeles, California, USA

¹⁵Department of Emergency Medicine, Regions Hospital, Saint Paul, Minnesota, USA

¹⁶Department of Anesthesiology, Danish Poisons Information Centre, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark

¹⁷Division of Clinical Pharmacology and Toxicology, Department of Emergency Medicine, University of Calgary, and Toxicology, Poison and Drug Information Service Alberta Health Services, Calgary, Alberta, Canada

¹⁸Department of Emergency Medicine, Upstate NY Poison Center and Upstate Medical University, Syracuse, New York, USA

¹⁹Department of internal medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India

²⁰Banner – University Medical Center Tuscon, University of Arizona College of Pharmacy, Tuscon, Arizona, USA

²¹Department of Medical Biology, Sacré-Coeur Hospital, University of Montréal, Montréal, Québec, Canada

Intravenous lipid emulsion (ILE) therapy is a novel treatment that was discovered in the last decade. Despite unclear understanding of its mechanisms of action, numerous and diverse publications attested to its clinical use. However, current evidence supporting its use is unclear and recommendations are inconsistent. To assist clinicians in decision-making, the American Academy of Clinical Toxicology created a workgroup composed of international experts from various clinical specialties, which includes representatives of major clinical toxicology associations. Rigorous methodology using the Appraisal of Guidelines for Research and Evaluation or AGREE II instrument

Received 20 January 2015; accepted 11 May 2015.

*The AACT Lipid Emulsion Therapy workgroup also consists of Marjorie BonHomme, MD and Sheldon Magder, MD.

Address correspondence to Dr Valéry Lavergne, Department of Medical Biology, Sacré-Coeur Hospital, University of Montréal, 5400 Boulevard Gouin Ouest, Montréal, Québec, H4J 1C5 Canada. Tel: 514-338-2222. Fax: 514-338-3307. E-mail: valerylavergne@gmail.com

was developed to provide a framework for the systematic reviews for this project and to formulate evidence-based recommendations on the use of ILE in poisoning. Systematic reviews on the efficacy of ILE in local anesthetic toxicity and non-local anesthetic poisonings as well as adverse effects of ILE are planned. A comprehensive review of lipid analytical interferences and a survey of ILE costs will be developed. The evidence will be appraised using the GRADE system. A thorough and transparent process for consensus statements will be performed to provide recommendations, using a modified Delphi method with two rounds of voting. This process will allow for the production of useful practice recommendations for this therapy.

Keywords Intravenous lipid emulsion; Fat emulsion; Lipid resuscitation; Recommendation; Efficacy; Adverse effect; Lipid interference

Introduction

Local anesthetic systemic toxicity (LAST) is a potentially severe iatrogenic occurrence with an estimated incidence of approximately 1 per 1000 procedures. The clinical presentation ranges from seizures and dysrhythmias to cardiac arrest. Treatment consisting of oxygenation, ventilation, atropine, and standard cardiac resuscitation is not always ineffective.¹ Overdoses with lipid-soluble substances, such as antidepressants and cardiac medications, rank 5th and 6th in the list of most common substance categories reported to the US National Poison Data System.² Although the fatality rate from the data available remains imprecise, neurotoxicity and cardiovascular toxicity associated with lipid-soluble substances may be severe and significant morbidity is common.

A brief historical review of the use of intravenous lipid emulsion (ILE) in medical toxicology starts in 1997, when an *in vivo* animal model of bupivacaine toxicity showed that in the presence of ILE the amount of bupivacaine required to induce LAST was significantly increased.³ It is almost a decade later, in 2006, that the first human case of LAST successfully treated with ILE therapy was reported.⁴ In 2008, with the hypothesis that other lipid-soluble drugs might also be influenced by this treatment, ILE was used in a patient with oral bupropion and lamotrigine toxicity after standard toxicology resuscitation was failing, with subsequent survival.⁵ Since the publication of that case report, ILE has been increasingly employed in anesthesia and medical toxicology.^{4,5} The American College of Medical Toxicology published an interim guidance statement regarding its use in 2011.⁶ Despite many reviews published in recent years, the literature is dominated by animal models with unclear generalizability to humans, numerous opinion articles, and anecdotal case reports of variable quality that are highly prone to publication bias.⁷⁻⁹

Previously, ILE was primarily used for parenteral nutrition, drug transport, or chemo-embolization. Currently, it has become part of the treatment options available to anesthesiologists, intensivists, emergency physicians, and medical toxicologists in the treatment of poisoning. Although the mechanisms of actions are still not entirely clear, three main hypotheses have been proposed: sequestration of the offending xenobiotic in an expanded plasma lipid phase (the "lipid sink" theory), alteration in ionic channel permeability (activation of voltage-gated calcium or sodium channels), and modification of fatty acid utilization by the poisoned myocardium (the "bioenergetics" theory).¹⁰

The present workgroup was established by the American Academy of Clinical Toxicology to produce evidence-based recommendations on the use of ILE in poisoning to aid clinicians in their decision-making in urgent situations. Recommendations are intended to rely on the best available data, although few controlled studies have been conducted on the use of ILE in humans. The non-standardized protocols used for ILE result in significant variability in management, both in the amount of ILE given as well as in the duration of treatment. The rapid clinical improvements reported in some published case reports have therefore fostered an enthusiasm for this new therapy, especially for patients who fail to respond to other treatments. Frequently, the dose and duration of ILE for treatment of lipophilic drug toxicity exceed the maximum accepted dosage used in the parenteral nutrition literature. Potential adverse effects and costs have neither been well studied nor reported.

There are numerous factors that create variability, and therefore pose difficulties in comparing studies. These factors include the large number of xenobiotics for which this therapy has been tried, inconsistencies in the amount, duration and constitution of ILE used, and the differences between oral poisoning and LAST, which is typically parenteral. Nevertheless, this workgroup has elected to proceed with the systematic identification, review, and critique of all available evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.¹¹ Since human case reports may reveal important information about toxicokinetics and there appears to be a temporal relationship between ILE administration and clinical improvement, this workgroup has opted to include case reports.

With the anticipated low-quality evidence, the term "guidelines" might not be appropriate for this endeavor. Nevertheless, because of the use of the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument (Appendix 1 available online at <http://informahealthcare.com/doi/abs/10.3109/15563650.1052498>), the results are based on a rigorous process of synthesis and methodology, which under the circumstances adds value to the current debate.¹² The workgroup has therefore chosen the wording "Recommendations" which will reflect the best available evidence at the time of publication.

Objectives of the workgroup

Our objectives are to summarize the available evidence on (1) the clinical efficacy of ILE with non-local anesthetic

poisoning; (2) the clinical efficacy of ILE with local anesthetic poisoning; and (3) the adverse effects of ILE divided into clinical effects and analytical interference. To fulfill these objectives, three systematic reviews and a comprehensive review on analytical interferences from ILE will be performed. Based on the evidence collected and the results of these systematic and comprehensive reviews, recommendations on the use of ILE in the context of poisoning will be developed. The clinical efficacy of ILE will be measured against current standards of care and alternative treatments, and balanced with its potential complications and costs.

Methodology

Group selection

At least two representatives from national and international medical toxicology associations have been delegated by their respective boards to serve on this workgroup. The number of representatives was selected according to the size of the associations' membership. In order to ensure that the workgroup was fully representative, and included different specialty stakeholders with the expertise needed to assess every aspect of this therapy, additional experts were recruited based on recommendations from various societies or on their particular clinical expertise. One participant was chosen because of expertise in epidemiology and guideline methodology, but will not participate in the voting of the recommendations. Two medical librarians were included in the workgroup to design and conduct systematic searches of the literature and to assist with article retrieval but are not voting members. Medical biochemists and non-clinician pharmacists will be excluded from voting, but will participate in assessing the quality of the data for the adverse effects profile of ILE. Participants divulged all potential conflicts of interests prior to inclusion in the workgroup (Table 1) and the final selection was done to avoid conflict of interest (financial, academic, or others) to respect the Institute of Medicine's most recent recommendations.¹³

The first meeting of the workgroup took place in Atlanta, Georgia, USA on September 29th, 2013. The majority of the members at the time were present either in person or by telephone ($N = 16/24$); one non-voting workgroup member was added after the meeting. The purpose of this meeting was to establish the methodology structure, and agree on a timeline and work division in order to produce recommendations that will be both rigorous and transparent. Decisions on methodology were based on majority votes (50% + 1).

Criteria for publication inclusion

Type of participants

The studied participants for the evaluation of the efficacy of ILE will be patients or animals to whom ILE was given. There will be no restriction on the context of the poisoning (acute or chronic), on the poison, or on the heterogeneity of the participants (e.g., special populations such as pediatric, chronic kidney disease, hepatic insufficiency, and

pregnancy). Studied participants for the search regarding adverse effects of ILE will include patients who received ILE either for poisoning or for other indications.

Type of interventions

ILE will be considered as the intervention of interest for the efficacy evaluation only if instituted, at least partially, for the purpose of treating poisoning. Studies in which ILE was instituted for other indications will be excluded. Any administration of ILE therapy (poisonings or total parental nutrition) will be reviewed to estimate the risk of adverse events.

Type of comparisons

Clinical efficacy of ILE versus other resuscitative therapies will be reviewed. When applicable, different formulations, dosages, and durations of ILE will be compared for efficacy or adverse events.

Type of outcomes

The primary outcome of interest is survival. Secondary outcomes, seizure duration, time to resolution of cardiac dysrhythmias, time and achievement of hemodynamic endpoints, (blood pressure, heart rate), neurological recovery (altered mental status and coma), and potential adverse events (pancreatitis, fat emboli, etc.) associated with ILE will also be evaluated.

Type of studies

Study designs that will be considered for inclusion in the systematic reviews are randomized controlled trials, non-randomized controlled trials, observational studies, case series/case reports, abstracts from clinical toxicology meetings (from 2000 onwards), abstracts from other specialties (from 2010 onwards), and animal studies. For the comprehensive review addressing analytical interferences due to ILE, reports of method and instrument evaluations published in peer-reviewed journals will be appraised. Additionally, abstracts from representative clinical toxicology meetings and clinical chemistry meetings from 2009 onwards as well as package inserts from widely used and situationally relevant assay methodologies will be included for consideration.

Publication selection

Search strategy

Two medical librarians (MM and AMN) will identify candidate studies for this review by conducting three searches. The first will be a systematic search on ILE in toxicology for the treatment both of local anesthetic toxicity and non-local anesthetic toxicity; results from this search will thus provide the basis for two of the three systematic reviews

Table 1. Workgroup participants.

Name	Association	Expertise
Voting members		
Sophie Gosselin, Canada	AACT	chair, emergency physician, medical toxicologist
Diane P. Calello, USA	AACT	pediatric emergency physician, medical toxicologist
Robert S. Hoffman, USA	AACT	emergency physician, medical toxicologist
Michael Levine, USA	AACT	emergency physician, medical toxicologist
Bryan D. Hayes, USA	AAPCC	pharmacist, clinical toxicologist
Christine Stork, USA	AAPCC	pharmacist, clinical toxicologist
Theodore C. Bania, USA	ACMT	emergency physician, medical toxicologist
Samuel J. Stellpflug, USA	ACMT	emergency physician, medical toxicologist
Ashish Bhalla, India	APAMT	internist, medical toxicologist
Andis Graudins, Australia	APAMT	emergency physician, medical toxicologist
Benoit Bailey, Canada	CAPCC	pediatric emergency physician, medical toxicologist
Ryan Chuang, Canada	CAPCC	emergency physician, medical toxicologist
Lotte C. G. Hoegberg, Denmark	EAPCCT	pharmacist, clinical toxicologist
Bruno Mégarbane, France	EAPCCT	critical care physician, medical toxicologist
Simon H. L. Thomas, UK	EAPCCT	internist, medical toxicologist
Sheldon Magder, Canada		cardiologist, critical care physician, electrophysiologist
Alexis F. Turgeon, Canada		anesthesiologist, critical care physician, epidemiologist, methodologist
Non-voting members		
Marjorie BonHomme, USA		medical biochemist
Brian M. Gilfix, Canada	CAMB	medical biochemist
Ami M. Grunbaum, Canada	CAMB	medical biochemist
Valéry Lavergne, Canada	GRADE	epidemiologist, methodologist
José A. Morais, Canada	CGS & ASN	internist, geriatrician, total parenteral nutrition specialist
Martin Morris, Canada		medical librarian
Andrea Nesbitt-Miller, Canada		medical librarian
Carol J. Rollins, USA	ASPEN	Pharmacist in nutritional support

to be produced by this workgroup. The second will be a systematic search on adverse effects of ILE and parenteral nutrition. The third search on lipid laboratory interferences will be conducted in order to provide supporting evidence during the analysis of the third systematic review, and will be thus comprehensive rather than systematic.

For each search, we will use a search strategy for Medline (via Ovid) that will be adapted to Embase (via Ovid), CINAHL (via EBSCO), BIOSIS Previews (via Ovid), Web of Science, Scopus, and the Cochrane Library/DARE, from inception to December 15th, 2014.

The Medline search strategies will comprise a combination of Medical Subject Headings or MeSH, title/abstract key words, truncations, and Boolean operators, and are given in full in Appendices 2–4 (available online at <http://informahealthcare.com/doi/abs/10.3109/15563650.1052498>). The first search will include the concepts of ILE and toxicology (including but not limited to calcium channel blockers, beta-blockers, and sodium channel blockers). The second search will include the concepts of ILE and parenteral nutrition, combined with the BMJ Clinical Evidence Adverse Effects filter (BMJ Clinical Evidence, 2012).

In addition, conference abstracts from the European Association for Poison Centres and Clinical Toxicologists, and the North American Congress of Clinical Toxicology (both from 2000 to 2014) and previous reviews will be hand-searched by various group members. Abstract from the Asia Pacific Association of Medical Toxicology will be searched from 2007 to 2014. Group members will perform cross-referencing of full-text articles. No limits will be

applied for language, and candidate studies in languages not known to any of the authors will be translated.

Publication exclusion

The workgroup will consider any original peer-reviewed article or abstract published in a peer-reviewed journal. Reviews, editorials, book chapters, and commentaries will be included only if they contained original data. Studies which after full-text review will be found not to contain enough data will be excluded. Animal studies will be excluded if the methods and results are uninterpretable or cannot be extrapolated to humans. Publications describing the use of ILE solely for the treatment of nutritional needs will be excluded from the efficacy systematic review, but will be included in the adverse effect systematic review. Pretreatment studies and experimental in vitro or ex vivo models will be excluded due to their inability to be generalizable to the context of human poisoning.

Reporting by subgroup

The workgroup will be divided into subgroups, each of which will be responsible for reviewing a different aspect of the therapy. A summary of the search strategy will be described in their distinct manuscript for each systematic review by the responsible subgroup and the librarians, according to the PRISMA statement.¹⁴ It will describe in detail the number of references retrieved in the initial search. The number of duplicates and excluded publications will be stated, with the

reason for exclusion (relevance, very poor quality, or publication type). Any disagreement in the exclusion process will be addressed explicitly.

Poison selection

All poisons for which ILE will be reported as a treatment for acute or chronic toxicity will be included for the systematic review. Poisons for which the group will determine that sufficient cases have been reported (more than 3 subjects) will be evaluated through the voting process, which is to occur at a later date.

Data extraction, synthesis, presentation, and interpretation

Data extraction

For each publication retained in each different database, the responsible subgroup will extract all relevant data into a standardized data extraction document. Relevant data that will be extracted will include demographic information, description of poisoning (amount of poison, timing, administration route, and coingestion), severity of poisoning (poison-specific clinical symptoms, signs, and relevant laboratory analyses), ILE administered (lipid formulation and concentration, use of a bolus (amount and timing of administration), use of an infusion (rate and duration), and total amount of lipid received converted in g/kg), concomitant treatments (type, dose, and duration), clinical outcomes (general and specific to the described poisoning), adverse effects of therapy (type, severity, and timing), and duration of follow-up. At this stage, no calculation, inference, or interpretation will be attempted. All publications likely to be excluded (according to the previous criteria) will be marked for reevaluation by the expert subgroup. To reduce the risk of errors, two independent reviewers will evaluate each publication. To ensure uniformity, the group leader will merge individual data extraction flow sheets. If observational studies or randomized controlled trials are included, the epidemiologist will assist the evaluation of the quantitative measure of effect and quality of evidence for clinical outcomes.

Evaluation of extracted data

For each publication included in the specific poison database, the subgroup will first evaluate publications marked for exclusion. A publication will be rejected only if all members of the subgroup agree. If there is a strong disagreement on the inclusion or exclusion of a determined publication, the chair will adjudicate. When the final summaries will be presented to the workgroup for the recommendations assessment, the arguments for and against inclusion of a particular publication will also be presented for transparency. Each individual publication will be assessed in regards to its quality for clinical outcomes or adverse effects accordingly with recognized reporting guidelines.¹⁵⁻²⁰ The final level of evidence will be reported as per the GRADE system (methodological biases, indirectness, imprecision, and error).^{11,21} Also, the effect of

ILE will be reported for each clinical outcome (descriptive value and/or comparative values, such as risk difference, relative risk, and *p* value, if applicable). Because of the controversy as to which kinetic outcome (free drug concentration or apparent half-life changes) is valid to appraise success of ILE, they will only be reported if measured.

Data Synthesis

Following the previous steps, the subgroup will create a summary sheet. Data will be regrouped to allow synthesis principally by poison or group of poisons, and if feasible, by intervention and by subpopulation. The quality of the evidence will be summarized for each outcome (Appendix 5 available online at <http://informahealthcare.com/doi/abs/10.3109/15563650.1052498>). The effect of ILE and risk of adverse effects will be summarized qualitatively or quantitatively for each outcome. For the review of analytical interferences, the data will be grouped by analyte and/or methodology. Any general comments on the reviewed literature will be added to the summary sheet. The definitions and terminology used are presented in Table 2.

Lipid emulsion costs

A survey will be distributed internationally to pharmacists of health care agencies and health care organizations to assess the acquisition costs and patient charges for different ILE formulations and comparative treatments available in their countries. This is not intended to provide a rigorous cost analysis study or to assess cost-effectiveness of ILE. Rather, it will give an overall idea of the monetary costs associated with administration of various ILE formulations, their adequate storage and expiry date required for availability.

Recommendations on the use of ILE

Statement proposal

After reviewing and summarizing the available literature, the subgroup will propose a series of statements concerning the use of ILE in poisoning. These statements will take into account the quality of evidence, the relative importance

Table 2. Definitions/Terminology.

Poison: A xenobiotic (exogenous chemical, including medication) or an endogenously available chemical (e.g., iron, copper, and vitamins) resulting from exogenous exposure with the potential to cause toxicity.
Poisoning: Exposure to a poison, regardless of intent. It includes intoxication, toxicity, and overdose.
Adverse outcome: Significant clinical effect following poisoning or treatment. An adverse outcome can be critical (death or major end-organ damage such as neurological sequelae) or non-critical (such as coma with otherwise stable hemodynamic status).
Severe poisoning: Exposure to a poison causing or having the potential to cause an adverse outcome if untreated.
Complications: Adverse outcome related to the treatment. These can be critical (digit ischemia leading to amputation) or non-critical (chemical pancreatitis).

of the outcomes, expected clinical course without ILE, the availability of other therapies, the magnitude and the precision of the effect, the balance between benefits and harms, and the costs of the procedure.

Prototype statements

1. General statement: (we recommend/we suggest/neutral position/no agreement reached) to (give/not give) ILE in poisoning with "X."
2. Specific statements: If there is support, other statements will be submitted: indications for initiating ILE (ingestion dose, drug concentration, special population, symptoms, and clinical markers), type of ILE regimen (dose, duration, rate, and formulation of ILE), and any other statement particular to the poison deemed significant by the subgroup (e.g., alternative therapy and antidote).

The subgroup will submit the following documents to the workgroup: complete publications, merged flow sheet, summary sheet, and the proposed voting statements. At any step throughout the process, if there is a strong disagreement or dissent, the issues will be brought to the entire workgroup for review.

Voting procedure

Since much of the literature reviewed is likely to be of low methodological quality, the majority of recommendations will be based on a consensus of expert opinions. Therefore, a rigorous voting procedure will be implemented to ensure transparency and reproducibility. The modified Delphi method (i.e., an iterative consultation of experts on a given subject) was chosen to reach a formal consensus on proposed voting statements. Two rounds of consultation are scheduled before the final version is submitted.

For the first round, the subgroup will submit statements to each workgroup member who anonymously will indicate their level of agreement and include comments. Approval for the proposed statement will be recorded on a 9-point Likert scale (with 1 being completely against and 9 being completely for the proposed statement). Every member will be encouraged to expand on or challenge proposed statements.

After completion of the first round, votes and comments will be summarized. The RAND/UCLA Appropriateness Method (a method of statistical measurement frequently used and adapted to all panel sizes) will be used to quantify the votes.²² The median values and the lower/upper quartiles will be reported and the disagreement indexes calculated. Median values ranging from 7 to 9 will reflect that the workgroup is in favor of the proposed statement, 4–6 will reflect a neutral position, and 1–3 will reflect that the workgroup is not in favor of the statement. The disagreement index, defined as the interpercentile range divided by the interpercentile range adjusted for symmetry, describes the dispersion of ratings more effectively than the mean absolute deviation from the

median. Index values less than or equal to 1 will indicate agreement.²³

A standardized form will then be resubmitted to each participant with his or her vote, summary statistics, and workgroup comments and modified statements. The second voting round will take place after a meeting where the results of the first round of the votes will be discussed in a face-to-face meeting for the majority of the workgroup members and others joining by teleconferencing. All subgroups will present the evidence a second time, that is, potential risks, costs, alternative treatments, and clinical benefit, for every reviewed poison. After this presentation, the workgroup will take time to deliberate these findings. Each statement will then be revoted privately and anonymously.

The voting procedure will result in providing strength of recommendations (see Fig. 1). Because of the restricted number of experts voting, if dissent remains, the final decision and debate will be explained in the official recommendation document for transparency. Interpretation of each level of strength of recommendation is explained in Table 3.

Values and preferences

Values and preferences of the patients will not be evaluated as part of this work (after discussion with a representative of the AGREE consortium) since this is no homogenous population. The clinical situations evaluated being in a resuscitative context pose inherent limitations to the timeliness of decision-making by clinicians and the ability of patients to evaluate their own risk–benefit considerations. However, values and preferences susceptible to influence the votes of the stakeholders will be evaluated at the end of the process by a survey conducted by the methodologist.

Writing and review process

The Board of Trustees of the American Academy of Clinical Toxicology (AACT), as the main sponsoring organization, has first endorsed this methodology manuscript, while other participating organizations provided comments through their representatives. Four distinct manuscripts will be prepared for the evidence reviews and will be submitted through standard peer-reviewed publication process. No supplementary review or endorsement will be required by AACT for these scientific reviews. The last manuscript which is to include the recommendations will be submitted to AACT and other participating organizations for endorsement prior to publication.

Implementation and applicability

Following endorsement by AACT and publication of the recommendations, these recommendations will be available on AACT website for dissemination. Members of the workgroup intend to conduct an international survey of end-user clinicians to identify the impact of the recommendations on their practice.




Fig. 1. Delphi method (two rounds) for each recommendation.

Updating

These recommendations will be updated if there is a significant change in the evidence, at the request of AACT or no later than 5 years after publication. A search strategy will be registered in different search engines for updates.

Conclusion

ILE therapy for poisoning is a recent development in clinical toxicology. The heterogeneity of the literature warrants a thorough review and appraisal of the evidence. Rigorous methodology combined with a transparent recommendations process development will assist clinicians in making choices

when treating patients with substances potentially amenable to treatment with ILE therapy.

Funding

Participants did not receive honoraria. The AACT provided funding for conference calls. Dr Turgeon and Dr Lavergne are recipients of a career award from the Fonds de Recherche du Québec – Santé (FRQS).

Acknowledgments

The workgroup wishes to thank Ms Ellen Pak and Ms Sarah Shiffert for their administrative assistance in organizing meetings.

Table 3. Strength of recommendation and level of evidence scaling for clinical outcomes.

Strength of recommendation (consensus-based)	Level of evidence (based on GRADE system)
Level 1 = Strong recommendation (The course of action is considered appropriate by the large majority of experts with no major dissension. The panel is confident that the desirable effects of adherence to the recommendation outweigh the undesirable effects.)	Grade A = High level of evidence (the true effect lies close to our estimate of the effect.)
Level 2 = Weak recommendation (The course of action is considered appropriate by the majority of experts but some degree of dissension exists among the panel. The desirable effects of adherence to the recommendation probably outweigh the undesirable effects.)	Grade B = Moderate level of evidence (the true effect is likely to be close to our estimate of the effect, but there is a possibility that it is substantially different.)
Level 3 = Neutral position (The course of action is neither preferred nor rejected by the majority of experts, either due to a balance in the desirable and undesirable effects of adherence to the recommendation or due to major uncertainties to its evaluation.)	Grade C = Low level of evidence (the true effect may be substantially different from our estimate of the effect.)
No recommendation = No agreement was reached by the group of experts.	Grade D = Very low level of evidence (our estimate of the effect is just a guess, and it is very likely that the true effect is substantially different from our estimate of the effect.)

Declaration of interest

The authors report no declarations of interest. The authors alone are responsible for the content and writing of the paper.

References

- Sites BD, Taenzer AH, Herrick MD, Gilloon C, Antonakakis J, Richins J, Beach ML. Incidence of local anesthetic systemic toxicity and postoperative neurologic symptoms associated with 12,668 ultrasound-guided nerve blocks: an analysis from a prospective clinical registry. *Reg Anesth Pain Med* 2012; 37:478–482.
- Mowry JB, Spyker DA, Cantilena LR, Jr., Bailey JE, Ford M. 2012 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 30th annual report. *Clin Toxicol* 2013; 51:949–1229.
- Weinberg GL, VadeBoncouer T, Ramaraju GA, Garcia-Amaro MF, Cwik MJ. Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats. *Anesthesiology* 1998; 88:1071–1075.
- Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. *Anesthesiology* 2006; 105:217–218.
- Sirianni AJ, Osterhoudt KC, Calello DP, Muller AA, Waterhouse MR, Goodkin MB, et al. Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. *Ann Emerg Med* 2008; 51:412–415, 415 e1.
- American College of Medical Toxicology. ACMT position statement: interim guidance for the use of lipid resuscitation therapy. *J Med Toxicol* 2011; 7:81–82.
- Jamaty C, Bailey B, Larocque A, Notebaert E, Sanogo K, Chauny JM. Lipid emulsions in the treatment of acute poisoning: A systematic review of human and animal studies. *Clin Toxicol* 2010; 48:1–27.
- Cave G, Harvey M, Graudins A. Review article: Intravenous lipid emulsion as antidote: A summary of published human experience. *Emerg Med Australas* 2011; 23:123–141.
- Waring WS. Intravenous lipid therapy: A systematic review of published case reports. *Clin Toxicol* 2012; 50:365–366.
- Butterworth JF 4th. Models and mechanisms of local anesthetic cardiac toxicity: a review. *Reg Anesth Pain Med* 2010; 35:167–176.
- Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is “quality of evidence” and why is it important to clinicians? *BMJ* 2008; 336:995–998.
- Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ* 2010; 182:E839–E842.
- Institute Of Medicine. *Clinical Practice Guidelines We Can Trust*. Washington DC: National Academies Press, 2011.
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009; 339:b2535.
- Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010; 340:c332.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008; 61:344–349.
- Gagnier JJ, Riley D, Altman DG, Moher D, Sox H, Kienle G, CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. *Dtsch Arztebl Int* 2013; 110:603–608.
- Lavergne V, Ouellet G, Bouchard J, Galvao T, Kielstein JT, Roberts DM, et al. Guidelines for reporting case studies on extracorporeal treatments in poisonings: methodology. *Semin Dial* 2014; 27:407–414.
- Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *PLoS Biol* 2010; 8:e1000412.
- Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, et al. Guidelines for submitting adverse event reports for publication. *Pharmacoepidemiol Drug Saf* 2007; 30:367–373.
- Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, et al. Incorporating considerations of resources use into grading recommendations. *BMJ* 2008; 336:1170–1173.
- Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA appropriateness method user's manual. Santa Monica, CA 2011. Available from: <http://www.rand.org>. (Last Accessed on 15 December 2014).
- Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the conference on guideline standardization. *Ann Intern Med* 2003; 139:493–498.

Supplementary material available online

Supplementary Appendix 1–5 available online at <http://informahealthcare.com/doi/abs/10.3109/15563650.1052498>

Supplementary material for Gosselin, S et al. Methodology for AACT evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning. Clinical Toxicology, 2015; 53:557–564.

Appendix 1. Appraisal of guidelines for research and evaluation (agree) II instrument

Scope and purpose

1. The overall objective(s) of the guideline is (are) specifically described.
2. The health question(s) covered by the guideline is (are) specifically described.
3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.

Stakeholder involvement

4. The guideline development group includes individuals from all the relevant professional groups.
5. The views and preferences of the target population (patients, public, etc.) have been sought.
6. The target users of the guideline are clearly defined.

Rigor of development

7. Systematic methods were used to search for evidence.
8. The criteria for selecting the evidence are clearly described.
9. The strengths and limitations of the body of evidence are clearly described.
10. The methods for formulating the recommendations are clearly described.
11. The health benefits, side effects, and risks have been considered in formulating the recommendations.
12. There is an explicit link between the recommendations and the supporting evidence.
13. The guideline has been externally reviewed by experts prior to publication.
14. A procedure for updating the guideline is provided.

Clarity of presentation

15. The recommendations are specific and unambiguous.
16. The different options for management of the condition are clearly presented.
17. Key recommendations are easily identifiable.

Applicability

18. The guideline describes facilitators and barriers to its application.
19. The guideline provides advice and/or tools on how the recommendations can be put into practice.

20. The potential resource implications of applying the recommendations have been considered.
21. The guideline presents monitoring and/ or auditing criteria.

Editorial independence

22. The views of the funding body have not influenced the content of the guideline.
23. Competing interests of guideline development group members have been recorded and addressed.

Appendix 2. Medline (ovid) search strategy for lipid emulsion therapy efficacy

1. exp Fat Emulsions, Intravenous/
2. lipid rescue.ti,ab,kw.
3. (lipid adj3 emulsi*).mp.
4. (fat adj3 emulsi*).mp.
5. ((lipid or fat*) adj5 bolus).mp.
6. (lipid adj3 (resuscitat* or therap* or infus*)).mp.
7. (ILE adj5 (lipid* or emulsi* or fat*)).mp.
8. (IFE adj5 (lipid* or emulsi* or fat*)).mp.
9. (lipid adj3 sink*).mp.
10. (lipid adj3 sequest*).mp.
11. intravenous* lipid*.ti,ab,kw.
12. intralipid*.mp.
13. or/1-12
14. exp Cardiovascular Agents/
15. exp Sodium Channel Blockers/
16. exp Calcium Channel Blockers/
17. exp Adrenergic beta-Antagonists/
18. ((sodium or Na*) adj3 channel block*).ti,ab,kw.
19. ((calcium or Ca*) adj3 channel block*).ti,ab,kw.
20. (beta adj3 block*).ti,ab,kw.
21. B-blocker.ti,ab,kw.
22. exp Central Nervous System Depressants/
23. exp Psychotropic Drugs/
24. exp Anti-Arrhythmia Agents/
25. local an?esthetic*.mp.
26. exp Amitriptyline/
27. amitriptyline.mp.
28. exp Bupropion/
29. bupropion.mp.
30. exp Chloroquine/
31. chloroquine.mp.
32. chlorpromazine.mp.
33. clomipramine.mp.
34. cocaine.mp.
35. exp Dothiepin/
36. (dosulepin or dothiepin).mp.
37. glyphosate.mp.

38. haloperidol.mp.
39. lamotrigine.mp.
40. olanzapine.mp.
41. propofol.mp.
42. quetiapine.mp.
43. exp Sertraline/
44. sertraline.ti,ab,kw.
45. zopiclone.mp.
46. ropivacaine.mp.
47. levobupivacaine.mp.
48. lignocaine.mp.
49. diazepam.mp.
50. exp Carnitine/
51. carnitine.ti,ab,kw.
52. exp Poisoning/
53. poison*.ti,ab,kw.
54. exp Noxae/ae, po [Adverse Effects, Poisoning]
55. po.fs.
56. ae.fs.
57. to.fs.
58. exp Street Drugs/
59. (lipophilic adj3 (drug* or toxin*)).ti,ab,kw.
60. overdos*.ti,ab,kw.
61. exp Antidotes/
62. antidote*.ti,ab,kw.
63. (toxic* or intoxic* or pharmacotoxic*).ti,ab,kw.
64. Resuscitation/
65. resuscitat*.ti,ab,kw.
66. or/14-65
67. 13 and 66

Appendix 3. Medline (ovid) search strategy for lipid emulsion therapy adverse effects

1. exp Fat Emulsions, Intravenous/
2. lipid rescue.ti,ab,kw.
3. (lipid adj3 emulsi*).mp.
4. (fat adj3 emulsi*).mp.
5. ((lipid or fat*) adj5 bolus).mp.
6. (lipid adj3 (resuscitat* or therap* or infus*)).mp.
7. (ILE adj5 (lipid* or emulsi* or fat*)).mp.
8. (IFE adj5 (lipid* or emulsi* or fat*)).mp.
9. (lipid adj3 sink*).mp.
10. (lipid adj3 sequest*).mp.
11. intravenous* lipid*.ti,ab,kw.
12. intralipid*.mp.
13. exp Parenteral Nutrition/
14. (parenteral* adj3 nutrition*).ti,ab,kw.
15. (parenteral* adj3 (feed* or fed)).ti,ab,kw.
16. TPN.ti,ab.
17. or/1-16
18. ae.fs.
19. to.fs.

20. po.fs.
21. co.fs.
22. (safe or safety).ti,ab.
23. side effect\$.ti,ab.
24. ((adverse or undesirable or harm\$ or serious or toxic) adj3 (effect\$ or reaction\$ or event\$ or outcome\$)).ti,ab.
25. exp Product Surveillance, Postmarketing/
26. exp Adverse Drug Reaction Reporting Systems/
27. exp Clinical Trials, Phase IV as Topic/
28. exp Poisoning/
29. exp Substance-Related Disorders/
30. exp Drug Toxicity/
31. exp Abnormalities, Drug-Induced/
32. exp Drug Monitoring/
33. exp Drug Hypersensitivity/
34. (toxic* or intoxic* or complication\$ or noxious or tolerability).ti,ab.
35. exp Postoperative Complications/
36. exp Intraoperative Complications/
37. or/18-36
38. 17 and 3

Appendix 4. Medline (ovid) search for lipid emulsion therapy laboratory interferences

1. exp lipid emulsion/
2. exp hyperlipidemia/
3. (lipid? or *lipid/ or *lipids/).ti,ab.
4. intralipid.ti,ab.
5. (fat\$ adj3 emulsi*).ti,ab.
6. liposyn.ti,ab.
7. (lip?emi\$1 or lipid?emi\$1).ti,ab.
8. (hyperlip?emi\$1 or hyperlipid?emi\$1).ti,ab.
9. or/1-8
10. (blood or serum or sera or platelet* or plasma or h?ematolog*).ti,ab.
11. (erythrocyte* or h?emocyte* or leukocyte*).ti,ab.
12. exp lipid blood level/
13. (lipid adj3 interfer*).ti,ab.
14. exp hyperlipidemia/
15. (lip?emi\$1 or lipid?emi\$1).ti,ab.
16. (hyperlip?emi\$1 or hyperlipid?emi\$1).ti,ab.
17. or/10-16
18. exp analytical error/
19. interference*.tw.
20. ((diagnos* or test* or laborator* or analys?s or analytic*) adj5 (false or error\$1 or erroneous or efficien* or inefficien* or delay* or interfere* or turnaround or unreliab* or distort*)).ti,ab.
21. false positive*.ti,ab.
22. false negative*.ti,ab.
23. (observer\$ adj3 variation\$).ti,ab.
24. or/18-23
25. 17 and 24

Appendix 5. Summary of quality of evidence for clinical outcomes: GRADE system.

Initial grade based on studies design	Reduce grade	Raise grade	Final grade	Reporting
Randomized trial = high	<i>Study quality</i> <ul style="list-style-type: none"> Serious (-1) or very serious (-2) limitation to study quality 	<i>Strength of association</i> <ul style="list-style-type: none"> Strong evidence of association (RR > 2) based on consistent evidence from 2 or more observational studies, with no plausible confounders (+ 1) equivalent to magnitude of effect. Or very strong evidence of association (RR > 5) based on direct evidence with no major threats to validity (+ 2) 	High	A
Observational study = low	<i>Consistency</i> <ul style="list-style-type: none"> Important inconsistency (-1) 	<ul style="list-style-type: none"> Evidence of a dose response gradient (+ 1) 	Moderate	B
Any other evidence = very low	<i>Directness</i> <ul style="list-style-type: none"> Some (-1) or major (-2) uncertainty about directness Imprecise or sparse data (-1) High probability of reporting bias (-1) 	<ul style="list-style-type: none"> All plausible confounders would have reduced the effect (+ 1) 	Low	C
			Very Low	D